Concord Biotech Stock Price Analysis and Quick Research Report. Is Concord Biotech an attractive stock to invest in?

Stock investing requires careful analysis of financial data to determine a company's true net worth. This is generally done by examining the company's profit and loss account, balance sheet and cash flow statement, which can be time-consuming and cumbersome.

Examining a company's financial ratios is an easier way to determine its performance, which can help to make sense of the overwhelming amount of information in its financial statements. 

Here are a few indispensable ratios that should be a part of every investor’s research process, or, in simpler words, how to analyse Concord Biotech. 

• PE ratio: Price to Earnings ratio, which indicates how much an investor is willing to pay for a share for every rupee of earnings. A general rule of thumb is that shares trading at a low P/E are undervalued (it depends on other factors too). Concord Biotech has a PE ratio of 47.1319992874532 which is high and comparatively overvalued.

• Return on Assets (ROA): Return on Assets measures how effectively a company can earn a return on its investment in assets. In other words, ROA shows how efficiently a company can convert the money used to purchase assets into net income or profits. Concord Biotech has ROA of 12.3289% which is a bad sign for future performance. (Higher values are always desirable.)

• Current ratio: The current ratio measures a company's ability to pay its short-term liabilities with its short-term assets. A higher current ratio is desirable so that the company could be stable to unexpected bumps in business and economy. Concord Biotech has a Current ratio of 7.4455.

• Return on equity: ROE measures the ability of a firm to generate profits from its shareholders' investments in the company. In other words, the return on equity ratio shows how much profit each rupee of common stockholders’ equity generates. Concord Biotech has a ROE of 13.739%. (Higher is better)

• Debt to equity ratio: It is a good metric to check out the capital structure along with its performance. Concord Biotech has a Debt to Equity ratio of 0 which means that the company has low proportion of debt in its capital.

• Sales growth: Concord Biotech has reported revenue growth of -12.0838% which is poor in relation to its growth and performance. 

• Operating Margin: This will tell you about the operational efficiency of the company. The operating margin of Concord Biotech for the current financial year is 35.7393862593134%.

• Dividend Yield: It tells us how much dividend we will receive in relation to the price of the stock. The current year dividend for Concord Biotech is Rs 7.55 and the yield is 0.6%.

• Earnings Per Share: It tells us how much profit is allocated to to each outstanding share of a common stock. The latest EPS of Concord Biotech is Rs 26.9456. The higher the EPS, the better it is for investors. 

One can find all the Financial Ratios of Concord Biotech in Ticker for free. Also, one can get the intrinsic value of Concord Biotech by using Valuation Calculators, which are available with a Finology ONE subscription. 

Concord Biotech FAQs

Q1. What is Concord Biotech share price today?
Ans: The current share price of Concord Biotech is Rs 1270.

Q2. What is the market capitalisation of Concord Biotech?
Ans: Concord Biotech has a market capitalisation of Rs 13286.257908 Cr., calculated based on its latest share price.

Q3. What are the P/E and P/B ratios of Concord Biotech?
Ans: The PE ratio of Concord Biotech is 47.1319992874532 and the P/B ratio of Concord Biotech is 6.38472010794702, showing how the stock is valued against its earnings and book value.

Q4. What is the 52-week high and low of Concord Biotech share?
Ans: The 52-week high share price of Concord Biotech is Rs 1615, and the 52-week low share price of Concord Biotech is Rs 987.

Q5. Does Concord Biotech pay dividends?
Ans: Currently, Concord Biotech pays dividends. Dividend yield of Concord Biotech is around 0.6%.

Q6. What are the face value and book value of Concord Biotech shares?
Ans: The face value of Concord Biotech shares is Rs 1, while the book value per share of Concord Biotech is around Rs 198.9124. Face value is the nominal value set by the company, whereas book value reflects its accounting worth.

Q7. What is the debt of Concord Biotech?
Ans: Concord Biotech has a total debt of Rs 0 Cr., which affects investor sentiment and financial stability. 

Q8. What are the ROE and ROCE of Concord Biotech?
Ans: The ROE of Concord Biotech is 13.739% and ROCE of Concord Biotech is 18.3786%. ROE shows how efficiently the company is generating profit from shareholders’ equity, while the ROCE is reflects how efficiently the company uses its capital to generate returns.

Q9. Is Concord Biotech a good buy for the long term?
Ans: The Concord Biotech long-term outlook depends on debt levels, earnings growth, and sector trends. If it sustains profits and manages debt well, it may be considered for long-term investment.

Q10. Is Concord Biotech undervalued or overvalued?
Ans: Based on valuation ratios like P/E, P/B, and EV/EBITDA, one can analyse whether the Concord Biotech appears undervalued or overvalued at current levels. You can check detailed valuation metrics and peer comparisons on Finology Ticker.

Q11. How to check Concord Biotech’s financials?
Ans: You can review Concord Biotech’s financial statements - including balance sheet, income statement, and quarterly results - on Finology Ticker.